|
rs1799939
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A polymorphism, RETp (G691S), in the intracellular juxtamembrane domain of RET, which enhances signaling by glial cell-derived neurotrophic factor has been described and studied previously in pancreatic cancer, medullary thyroid cancer, the multiple endocrine neoplasia 2 syndromes, and recently in cutaneous malignant melanoma.
|
22189301 |
2012 |
|
rs1805008
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A strong association between CM and red hair was identified for rs1805007, and rs1805008 in the <i>MC1R</i> gene was mainly associated with red hair.
|
31612033 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis.
|
30997532 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis.
|
30997532 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
|
rs1805006
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Although our findings need to be confirmed by independent and larger studies we have described for the first time the association of D84E variant of the alpha-MSH receptor 1 gene as an independent risk factor for an earlier onset of cutaneous malignant melanoma.
|
18657399 |
2008 |
|
rs202042867
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although our findings need to be confirmed by independent and larger studies we have described for the first time the association of D84E variant of the alpha-MSH receptor 1 gene as an independent risk factor for an earlier onset of cutaneous malignant melanoma.
|
18657399 |
2008 |
|
rs121913366
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Among 41 response-evaluable patients, 2 (5 %) patients with cutaneous melanoma (one with BRAF L597R mutant melanoma) had partial responses.
|
27650277 |
2017 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
|
23568549 |
2013 |
|
rs1131691014
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
|
23568549 |
2013 |
|
rs878854066
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
|
23568549 |
2013 |
|
rs121912654
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
|
23568549 |
2013 |
|
rs1695
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
|
23568549 |
2013 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the target of treatment for patients with metastatic melanoma.
|
23211290 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the target of treatment for patients with metastatic melanoma.
|
23211290 |
2013 |
|
rs1544410
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BsmI (rs1544410) and FokI (rs2228570) vitamin D receptor polymorphisms, smoking, and body mass index as risk factors of cutaneous malignant melanoma in northeast Italy.
|
28884047 |
2017 |
|
rs2228570
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BsmI (rs1544410) and FokI (rs2228570) vitamin D receptor polymorphisms, smoking, and body mass index as risk factors of cutaneous malignant melanoma in northeast Italy.
|
28884047 |
2017 |
|
rs10492396
|
|
|
0.010 |
GeneticVariation |
BEFREE |
By performing false-positive report probability corrections and stepwise Cox proportional hazards regression analyses, we identified significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 (CC vs. TT+TC: adjHR=2.10, 95% CI=1.38-3.18, P=0.0005), and FANCA rs62068372 (TT vs. CC+CT: adjHR=1.85, 95% CI=1.27-2.69, P=0.001).
|
25243787 |
2015 |
|
rs206118
|
|
|
0.010 |
GeneticVariation |
BEFREE |
By performing false-positive report probability corrections and stepwise Cox proportional hazards regression analyses, we identified significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 (CC vs. TT+TC: adjHR=2.10, 95% CI=1.38-3.18, P=0.0005), and FANCA rs62068372 (TT vs. CC+CT: adjHR=1.85, 95% CI=1.27-2.69, P=0.001).
|
25243787 |
2015 |
|
rs3752447
|
|
|
0.010 |
GeneticVariation |
BEFREE |
By performing false-positive report probability corrections and stepwise Cox proportional hazards regression analyses, we identified significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 (CC vs. TT+TC: adjHR=2.10, 95% CI=1.38-3.18, P=0.0005), and FANCA rs62068372 (TT vs. CC+CT: adjHR=1.85, 95% CI=1.27-2.69, P=0.001).
|
25243787 |
2015 |
|
rs62068372
|
|
|
0.010 |
GeneticVariation |
BEFREE |
By performing false-positive report probability corrections and stepwise Cox proportional hazards regression analyses, we identified significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 (CC vs. TT+TC: adjHR=2.10, 95% CI=1.38-3.18, P=0.0005), and FANCA rs62068372 (TT vs. CC+CT: adjHR=1.85, 95% CI=1.27-2.69, P=0.001).
|
25243787 |
2015 |
|
rs1057519874
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
|
25043693 |
2014 |